Clinical trials: Stage II Skin Cancer
Breast Cancer, Ovarian Cancer
A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
This study will evaluate the efficacy and safety of 6-mercaptopurine (6MP) in combination with methotrexate (MTX) in patients with breast or ovarian cancer who are known to have a BRCA (breast cancer gene) mutation.
- Trial name
- 6MP (NCT01432145)
- Testing
- 6-Mercaptopurine, Methotrexate
- Where
- United Kingdom
- Volunteers
- 74 people
- Sponsor
- University of Oxford
Melanoma
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
This phase I/II trial is designed to determine the maximum tolerated dose or the maximum administered dose of intratumoral administration of hu14.18-IL2 and to evaluate side effects of intratumoral hu14.18-IL2 when given alone…
- Trial name
- NCT03958383
- Testing
- hu14.18-IL2, Radiation Therapy, Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Wisconsin, Madison
Invasive Breast Cancer, Metastatic Breast Cancer
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
- Conditions
- Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT04448886
- Testing
- Pembrolizumab, Sacituzumab Govitecan
- Where
- 8 sites in United States
- Volunteers
- 110 people
- Sponsor
- Ana C Garrido-Castro, MD
Breast Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma
- Trial name
- NCT02153905
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00622466
- Testing
- paclitaxel, sorafenib tosylate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways after surgery may kill more tumor cells.
- Trial name
- NCT00024102
- Testing
- Standard Treatment, capecitabine
- Where
- 334 sites in United States, Canada and 1 more
- Volunteers
- 633 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
A single centre, single arm phase II study of alternating eribulin and hormonal therapy in 12 patients with locally advanced or metastatic breast cancer who have received at least one hormonal therapy and at least one…
- Trial name
- ALERT (NCT02681523)
- Testing
- Eribulin
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Angiosarcoma of Skin
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
This is a single-arm study evaluating the efficacy of injecting Talimogene Laherparepvec T-VEC into Cutaneous Angiosarcoma tumors.
- Trial name
- NCT03921073
- Testing
- T-VEC
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
HER-2 Positive Breast Cancer
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Purpose: This study is a single-arm, open-label phase II clinical trial testing the hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective, safe, and tolerable among patients with human…
- Trial name
- NCT01305941
- Testing
- Everolimus, Vinorelbine, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT03213041
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Triple-negative Breast Cancer
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemotherapy and surgery, with or without radiation therapy.
- Trial name
- NeoPACT (NCT03639948)
- Testing
- Carboplatin, Docetaxel, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Kansas Medical Center
Melanoma, Skin Cancer
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT02111863
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
The goal of this clinical research study is to learn if Xofigo® (also called Ra-223 dichloride) combined with hormone therapy and denosumab can help to control breast cancer that has spread to the bones and/or bone marrow.
- Trial name
- NCT02366130
- Testing
- Ra-223 dichloride, Denosumab, Hormone Therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
This is a phase I/II study to determine the safety and gain insight into the immune response of the immunologic agent dHER2+AS15 ASCI when administered in combination with lapatinib.
- Trial name
- NCT00952692
- Testing
- dHER2 + AS15 ASCI, Lapatinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Michael Morse, MD
Metastatic Breast Cancer
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Phase I: will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer.
- Trial name
- NCT00426556
- Testing
- Everolimus, Trastuzumab, Paclitaxel
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
In this study, patients with metastatic HER2-negative breast cancer will receive treatment with ixabepilone and sorafenib until disease progression or unacceptable toxicity occurs.
- Trial name
- NCT00825734
- Testing
- Sorafenib, Ixabepilone
- Where
- 15 sites in United States
- Volunteers
- 83 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
The primary purpose of this study is to help answer the following research questions: whether the chemotherapy combination therapy Pemetrexed-Carboplatin or Gemcitabine-Vinorelbine can help participants with advanced breast…
- Trial name
- NCT00325234
- Testing
- Pemetrexed, Carboplatin, Gemcitabine
- Where
- 22 sites in Germany, Italy and 3 more
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive…
- Trial name
- BYLieve (NCT03056755)
- Testing
- Alpelisib, Fulvestrant, Letrozole
- Where
- 94 sites in United States, Argentina and 17 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
The study drug cabozantinib works by inhibiting several different proteins which are believed to be involved in breast cancer tumor growth, its ability to spread, and its ability to form new blood vessels.
- Trial name
- NCT01441947
- Testing
- Cabozantinib, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Massachusetts General Hospital
Chemotherapy-induced Neutropenia
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.
- Trial name
- NCT01569087
- Testing
- empegfilrastim, filgrastim
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Biocad
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.